Table 1.
Sensitivity and Specificity of the Recombinant in-house HIV Dot Blot assay.
| Sample Group | No of Specimens with Indicated Results | ||
|---|---|---|---|
| Positive | Negative | Indeterminate | |
| Seronegative Subjects (180) | |||
| Healthy blood donors (176) | 0 | 176 | 0 |
| False Positive by ELISA† (4) | 0 | 0 | 4 |
| Other Clinical Conditions† (21) | 0 | 21 | 0 |
| Total | 0 (0%) | 176 (97.8%) | 4 (2.2%) |
| Seropositive Subjects† (125) | |||
| AIDS Patients (32) | 32 | 0 | 0 |
| Asymptomatic HIV Infected Subjects (28) | 28 | 0 | 0 |
| HIV-Infected Intravenous drug users (48) | 47 | 0 | 1 |
| Hemophilic infected subjects (17) | 15 | 0 | 2 |
| Total | 122 (97.6%) | 0 (0%) | 3 (2.4%) |
† Confirmed by Reference Western Blot Assay (Abbot Laboratories, USA) and Commercial RT-PCR Assay (Roche Molecular Diag., France).